Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2026-03-07 Capital/Financing Update
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Capital/Financing Update Classification · 95% confidence The document is an 'Ad-hoc' announcement regarding an amendment to a royalty agreement and new financing from Soleus Capital. It explicitly mentions 'Disclosure of inside information' under Article 17 of the EU Market Abuse Regulation (MAR). This type of corporate financing and contract amendment announcement falls under the 'Capital/Financing Update' category as it details the receipt of $20 million and future $25 million funding to secure the company's financial position.
2026-03-07 English
Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
Regulatory Filings Classification · 95% confidence The document is a press release issued by Heidelberg Pharma AG announcing the receipt of a development milestone payment from their partner, Takeda. It details the nature of the payment (clinical development milestone) and provides context about the partnership and the company's technology. Since this is a corporate news announcement regarding business operations and financing milestones that does not fit into specific categories like earnings releases or regulatory filings, it is classified as a general regulatory/corporate announcement (RNS).
2026-01-29 English
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2024 bis zum 30.11.2025
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a formal shareholder resolution (Gesellschafterbeschluss) from Heidelberg Pharma AG regarding its subsidiary, Heidelberg Pharma Research GmbH. It outlines the decision to utilize exemption provisions under Section 264 (3) of the German Commercial Code (HGB) regarding the preparation, audit, and disclosure of financial statements for the 2025 fiscal year. This is a regulatory corporate governance filing related to financial reporting obligations rather than an earnings release, annual report, or investor presentation. As it does not fit into specific categories like DVA (voting results) or 10-K, it is best classified as a general regulatory filing.
2026-01-19 German
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.12.2024 bis zum 30.11.2025
Regulatory Filings Classification · 95% confidence The document is a formal shareholder resolution (Gesellschafterbeschluss) from Heidelberg Pharma AG regarding its subsidiary, HDP G250 Beteiligungs GmbH. It outlines the decision to utilize exemption provisions under § 264 Abs. 3 HGB, which allows a subsidiary to be exempted from preparing, auditing, and publishing its own separate financial statements by being included in the parent company's consolidated financial statements. This is a standard corporate governance and regulatory compliance filing in Germany. Since it does not fit into specific categories like earnings releases, dividends, or board changes, and is a formal regulatory notification regarding financial reporting obligations, it is best classified as a Regulatory Filing.
2026-01-09 German
Heidelberg Pharma: Letter from the CEO
Legal Proceedings Report Classification · 95% confidence The document is a 'Letter from the CEO' issued by Heidelberg Pharma AG. It discusses corporate strategy, restructuring, clinical trial updates, and financing challenges. While it contains management commentary, it does not fit the specific criteria for a formal Management Report (MDA) or an Earnings Release (ER). It is a corporate communication disseminated via a regulatory news service (EQS Group). Since it does not fall into a more specific category like 10-K, IR, or IP, it is best classified as a general regulatory announcement.
2025-12-17 English
Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
Board/Management Information Classification · 100% confidence The document is an official ad-hoc announcement regarding the appointment of a new CEO and changes to the Executive Management Board of Heidelberg Pharma AG. This falls directly under the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2025-11-24 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.